VolitionRX Ltd. ( (VNRX) ) has released its Q3 earnings. Here is a breakdown of the information VolitionRX Ltd. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
VolitionRx Limited is a multi-national epigenetics company dedicated to advancing the science of epigenetics through the development and commercialization of simple, cost-effective blood tests for early disease detection and monitoring, focusing on critical areas such as cancer and sepsis.
In its third quarter of 2025, VolitionRx Limited reported significant progress in commercializing its Nu.Q platform, highlighted by new agreements with major companies Werfen and Hologic. These partnerships are expected to enhance the company’s presence in the human diagnostics market.
The company reported a 32% increase in revenue for the third quarter, alongside a reduction in operating expenses by 10% year-on-year. Additionally, the net loss decreased by 8% for the quarter, with a notable reduction in net cash used in operating activities by 33% compared to the previous year. VolitionRx also secured approximately $6.1 million from a public offering post-quarter.
VolitionRx’s strategic focus remains on securing further licensing agreements in the human diagnostics space, leveraging its success in the veterinary market. The company anticipates continued growth and innovation in its Nu.Q technology, aiming to contribute significantly to oncology and NETosis detection and monitoring.
Looking ahead, VolitionRx is optimistic about its future prospects, driven by ongoing discussions with leading diagnostic companies and the potential for diverse deal structures that could provide upfront and milestone payments, as well as recurring revenue streams.